AbbVie (BSP:ABBV34) Retained Earnings : R$-4,900 Mil (As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is AbbVie Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. AbbVie's retained earnings for the quarter that ended in Dec. 2023 was R$-4,900 Mil.

AbbVie's quarterly retained earnings declined from Jun. 2023 (R$8,683 Mil) to Sep. 2023 (R$4,608 Mil) and declined from Sep. 2023 (R$4,608 Mil) to Dec. 2023 (R$-4,900 Mil).

AbbVie's annual retained earnings increased from Dec. 2021 (R$17,683 Mil) to Dec. 2022 (R$25,094 Mil) but then declined from Dec. 2022 (R$25,094 Mil) to Dec. 2023 (R$-4,900 Mil).

AbbVie Retained Earnings Historical Data

The historical data trend for AbbVie's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AbbVie Retained Earnings Chart

AbbVie Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Retained Earnings

Get a 7-Day Free Trial

19,360.93

5,427.66

17,682.87

25,093.99

-4,899.80

AbbVie Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Retained Earnings	Get a 7-Day Free Trial															12,464.18	8,683.27	4,607.81	-4,899.80	-

AbbVie Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

AbbVie (BSP:ABBV34) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.

AbbVie (BSP:ABBV34) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AbbVie Inc (BSP:ABBV34) » Definitions » Retained Earnings

Comparable Companies

Traded in Other Exchanges

ABBV:USA ABBV:Mexico 1ABBV:Italy 4ABd:UK 0QCV:UK 4AB:Germany ABBV:Canada ABBV:Austria

Address

1 North Waukegan Road, North Chicago, IL, USA, 60064-6400

Website

http://www.abbvieinvestor.com

AbbVie is a pharmaceutical firm with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.

AbbVie (BSP:ABBV34) Headlines

No Headlines